Titel: CNS Cancer
Dateigröße in MByte: 24.
Herausgegeben von Erwin G. van Meir
15. August 2009 - pdf eBook
The volume will cover three areas of research in brain tumors: a) animal models for brain tumors, including spontaneous occurrence of brain tumors in mammals, transgenic models in rodents and transplant models; b) Prognostic factors and biomarkers; c) Therapeutic targets and targeting approaches to brain tumors.
Chapter 1: PDGF-Based Malignant Glioma Model in Rats and Mice.-
Chapter 2: Modeling Brain Tumors Using Avian Retroviral Gene Transfer.-
Chapter 3: Using Neurofibromatosis Type 1 Mouse Models to Understand Human Pediatric Low-Grade Gliomas.-
Chapter 4: Transgenic Mouse Models of CNS Tumors: Using Genetically Engineered Murine Models to Study the Role p21-Ras in Glioblastoma Multiforme.-
Chapter 5: Pten-Deficient Mouse Models for High-Grade Astrocytomas.-
Chapter 6: The NF1/p53 Knockout Transgenic Model for Malignant Glioma.-
Chapter 7: Conditional Models for Brain Tumors in Transgenic Mice.-
Chapter 8: Human Brain Tumor Cell and Tumor Tissue Transplantation Models.-
Chapter 9: Transformation of Human Brain Cells in Culture as Models for Brain Tumors.-
Chapter 10: History of Important Carcinogen-Induced Brain Tumor Cell Lines.-
Chapter 11: Neuro-Oncogenesis Induced by Nitroso-Compounds in Rodents and Strain-Specific Genetic Modifiers of Predisposition.-
Chapter 12: The Murine GL261 Glioma Experimental Model to Assess Novel Brain Tumor Treatments.-
Chapter 13: Spontaneous Occurrence of Brain Tumors in Animals: Opportunities as Preclinical Model Systems.-
Chapter 14: P53 Alterations in Brain Tumors.-
Chapter 15: The PTEN/PI3 Kinase Pathway in Human Glioma.-
Chapter 16: Value of 1p/19q and Other LOH Markers for Brain Tumor Diagnosis, Prognosis and Therapy.-
Chapter 17: Discovery of Genetic Markers for Brain Tumors by Comparative Genomic Hybridization.-
Chapter 18: Genomic Identification of Significant Targets in Brain Cancer.-
Chapter 19: Oncogenic Pathway Markers.-
Chapter 20: Aberrant EGFR Signaling in Glioma.-
Chapter 21: Mechanisms of Brain Tumor Angiogenesis.-
Chapter 22: Vaso-Occlusive Mechanisms that Intiate Hypoxia and Necrosis in Glioblastoma: The Role of Thrombosis and Tissue Factor.-
Chapter 23: Expression Profiling of Glioblastoma Defines Distinct Subtypes.-
Chapter 24: Proteomic Profiling of Human Brain Tumors.-
Chapter 25: Discovery of Biomarkers in the Cerebrospinal Fluid of Brain Tumor Patients.-
Chapter 26: Epigenetic Profiling of Gliomas.-
Chapter 27: Micro RNAs in the Central Nervous System and Potential Roles of RNA Interference in Brain Tumors.-
Chapter 28: Understanding Glioma Resistance to Temozolomide Therapy.-
Chapter 29: Markers of Cancer Stem Cells for Brain Tumor Prognosis.-
Chapter 30: Clinical Agents for the Targeting of Brain Tumor Vasculature.-
Chapter 31: GBM Neovascularization: Impact of Bone Marrow-Derived Cells and Evasive Mechanisms of Antiangiogenic Therapy.-
Chapter 32: Novel Phage and Viral Targeting Vehicles for Brain Tumor Therapy.-
Chapter 33: Impact of the Blood Brain Barrier on Brain Tumor Imaging and Therapy.-
Chapter 34: Targeting CXCR4 in Brain Tumors.-
Chapter 35: Molecular Targeting of IL-13Ra2 and EphA2 Receptor in GBM.-
Chapter 36: Brain Tumor Targets for Antibody-Mediated Immuno-Therapy.-
Chapter 37: STAT3 Oncogenic Signaling in Brain Tumors.-
Chapter 38: Inhibition of Ras Signaling in Brain Tumors.-
Chapter 39: HGF/c-Met Signaling and Targeted Therapeutics in Brain Tumors.-
Chapter 40: Combinatorial Therapeutic Strategy for Blocking Kinase Pathways in Brain Tumors.-
Chapter 41: Targeting of TRAIL Apoptotic Pathways for Glioblastoma Therapies.-
Chapter 42: The NF-kB Signaling Pathway in GBMs, Implications for Apoptotic and Inflammatory Responses and Exploitation for Therapy.-
Chapter 43: Targeting Endoplasmic Reticulum Stress for Malignant Glioma Therapy.-
Chapter 44: Targeting Adult and Pediatric Brain Cancer Stem Cells.-
Chapter 45: The Use of Retinoids as Differentiation Agents Against Medulloblastoma.-
Chapter 46: Herpes Simplex Virus 1 (HSV-1) for Glioblastoma Multiforme Therapy.-
Chapter 47: The Development of Targeted Cancer Gene-Therapy Adenoviruses for High-Grade Glioma Treatment.-
Chapter 48: Harnessing T-cell Immunity to Target Brain Tumors.-
Chapter 49: Glioma Invasion: Mechanisms and Therapeutic Challenges.-
Erwin G Van Meir is Professor of Neurosurgery and Hematology & Medical Oncology in the School of Medicine at Emory University. A native of Belgium, he obtained Bachelor's degrees in Biology and Education at the University of Fribourg, Switzerland. He pursued graduate studies in Molecular Virology at the University of Lausanne, Switzerland where he obtained his PhD in 1989. He then became interested in cancer and pursued postdoctoral work at the University Hospital in Lausanne and at the Ludwig Institute for Cancer Research in San Diego. In 1994 he became a Junior Faculty and Director of the Laboratory of Brain Tumor Biology and Genetics in the Neurosurgery Department at the University of Lausanne. In 1998 he joined Emory University in Atlanta, where he now serves as the Leader of the Winship Cancer Institute Molecular Pathways and Biomarkers scientific program and as the co-Director of the brain tumor working group.
For the past 20 years Dr. Van Meir's research has focused on defining the biological significance of specific genetic alterations for brain tumor development, with particular emphasis on extracellular signaling regulating heterotypic cell communication as in tumor angiogenesis, and translating this knowledge into new therapeutic approaches. His research is described in more than 140 peer-reviewed research papers and review articles in internationally recognized journals that have cumulated over 5,000 citations and received several awards. These contributions were presented in over 100 invited seminars worldwide and have furthered the understanding of cytokine expression for glioma biology, Turcot syndrome, the role of transcription factors p53 and HIF and of pro- and anti-angiogenesis factors IL-8, thrombospondin-1 and brain angiogenesis inhibitor-1 in brain tumor angiogenesis, hypoxia, and pseudopalisade formation. He also discovered novel biomarkers in the cerebrospinal fluid of brain tumor patients and developed novel therapeutic agents including oncolytic hypoxia-activated adenoviruses, pro-apoptotic galectin-3, anti-angiogenic vasculostatins and small molecule HIF/Hsp90/plectin1 inhibitors that are covered by several US and foreign patents. Perhaps most importantly, over his still young 20 year independent career Dr Van Meir has already mentored and trained over 60 postdoctoral fellows, students and visiting scientists, many of which now hold independent leading positions in Academia or Industry.
Dr Van Meir is an active member of the International Neuro-Oncology community and served on the Board of Directors of the Society for Neuro-Oncology from 2004-2008. He organized several international conferences on brain tumors, has served on the Scientific Committee of the European Association for Neuro-Oncology, the Scientific Advisory Board of the Southeastern Brain Tumor Foundation and is a current or former member of several other international cancer societies including the American Association for Cancer Research, the European Association for Cancer Research, and the American Society for Investigative Pathology.
Dr. Van Meir currently serves on the Editorial Board of Neuro-Oncology, Frontiers in Bioscience, and International Journal of Oncology and is a former Associate Editor of the International Journal of Cancer. He has served as a reviewer for over 30 international scientific journals and for grant proposals from public and private agencies including the US National Institutes of Health, the US Department of Defense, the Swiss National Science Foundation, the Swiss Cancer Society, the Wellcome Trust of the UK, Cancer Research UK, the Research Grants Council of Hong Kong, the Israel Science Foundation, The Belgian Fournier-Majoie and Baudouin Foundations and the Italian Association for Cancer Research.
He acknowledges present and past support by multiple funding agencies for his scientific work, including the US National Institutes of Health, the Swiss National Science Foundation, the Goldhirsh Foundation, the Charlotte Geyer Foundation, the Southeastern and National Brain Tumor Foundations, The Brain Tumor Society, the Pediatric Brain Tumor Foundation of the US, the American Brain Tumor Association, the Brain Tumor Foundation for Children, the Al Musella, Wayne O Rollins and Frances Wood Wilson Foundations, the Brain Tumor Trust, the Emory University Research Council and EmTechBio, the Swiss Cancer League and Anti-Cancer Foundations, the San Salvatore, Tossizza, Ott and Chuard-Smith Foundations, and the European Institute of Oncology.
Dieses eBook wird im PDF-Format geliefert und ist mit einem Wasserzeichen versehen.
Sie können dieses eBook auf vielen gängigen Endgeräten lesen.
Für welche Geräte?
Sie können das eBook auf allen Lesegeräten, in Apps und in Lesesoftware öffnen, die PDF unterstützen:
Öffnen Sie das eBook nach der automatischen Synchronisation auf dem Reader oder
Sie es manuell auf Ihr tolino Gerät mit der kostenlosen Software Adobe Digital Editions.
Andere eBook Reader
Laden Sie das eBook direkt auf dem Reader im Hugendubel.de-Shop herunter oder
Sie es mit der kostenlosen Software Sony READER FOR PC/Mac oder Adobe Digital Editions.
Für Tablets und Smartphones: Unsere Gratis tolino Lese-App
PC und Mac
Lesen Sie das eBook direkt nach dem Herunterladen Herunterladen über "Jetzt lesen" im Browser oder mit der kostenlosen Lesesoftware Adobe Digital Editions.
Die eBook-Datei wird beim Herunterladen mit einem nicht löschbaren
individuell markiert, sodass die Ermittlung und rechtliche Verfolgung des ursprünglichen Käufers
im Fall einer missbräuchlichen Nutzung der eBook-Datei möglich ist.
Bitte beachten Sie: Dieses eBook ist nicht auf Kindle-Geräten lesbar.
Ihr erstes eBook?
Hier erhalten Sie
alle Informationen rund um die digitalen Bücher